Antimicrobial resistance (AMR) is on the rise and poses a significant threat to global health, with the risk of modern medicines becoming ineffective. There is an extensive need for new antimicrobials to treat both bacterial and fungal infections.

The Antimicrobial Screening Facility at the University of Warwick is primed to support AMR research and aid in the discovery of new antibiotic and antifungal treatments. It is equipped with state-of-the-art equipment and a wealth of knowledge from expert academics in the drug discovery field.

Providing a wide range of testing, spanning from rapid antimicrobial susceptibility investigations to comprehensive studies into the way antimicrobials work (mode-of-action studies), we offer an efficient and cost-effective service for external clients from industry and academia.  

We can help you with:

  • Antimicrobial susceptibility testing against biosafety level 1 and 2 pathogens.
  • Investigations into evolving antimicrobial resistance and frequency of spontaneous mutation.
  • Synergy experiments (assessing how antimicrobials interact).
  • Cytotoxicity testing (assessing the toxicity of compounds or materials).
  • Anti biofilm experiments (studying the effectiveness of antimicrobials targeting bacteria that form thin films, a key defence mechanism).
  • Antimicrobial surface testing.

Find out more

To discuss your requirements in more detail and find out how we can help provide a solution to your challenge, contact Dr Jenny Littler, Senior Scientist in the Antimicrobial Screening Facility or Claire Gerard, Warwick Scientific Services Manager.

About AMR research at the University of Warwick

The University of Warwick has a wealth of expertise in AMR research which underpins the services provided by the Antimicrobial Screening Facility.

The University’s Sir Howard Dalton Centre is a network of academics driving research into AMR. It has recently received a £1.5 million donation from The Great Britain Sasakawa Foundation, which will facilitate collaborative research into AMR between the UK and Japan.  

Article provided by Medilink Midlands Patron the University of Warwick, click here to learn more. 

Latest Opportunities

Single manufacturer & supplier required for human skin patch: Formulation, manufacture, and packing

Opportunity Company:  Nottingham-based MedTech company Requires: Seeking a single manufacturer and supplier for the formulation,…

Medilink Midlands Job Vacancy - Innovation Adviser

About the job Innovation Adviser – Midlands region – Full time salary £40-45K – Home…

Global Business Innovation Programme: Health & Medical Technologies - Singapore

Innovate UK is inviting ambitious innovative companies to participate in its Global Business Innovation Programme…

Latest News

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep – Helping Gamers…

Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters…

EU MDR/IVDR Revision: A Gateway for Chinese Innovators Entering UK and EU Markets via EFEC

In a significant move for the global medtech landscape, the European Commission has initiated a…